Keystone Investment Trust plc
Interim Management Statement
for the three months ended 30 June 2014
Material Events
No material events, specifically in relation to the Company, occurred during
the period to 30 June 2014.
Dividends
In the period a first interim dividend of 18p per ordinary share was paid on 27
June 2014 to shareholders on the register on 30 May 2014. The shares were
marked ex-dividend on 28 May 2014.
Performance - Total Return
3 Months 1 Year 3 Years 5 Years
Share Price 3.9% 16.1% 56.6% 130.1%
Net Asset Value 1.7% 17.5% 54.7% 132.0%
FTSE All-Share Index 2.2% 13.1% 29.2% 96.7%
Source: Thomson Reuters Datastream
Share Price and Discount
For the Three Months Ended
30 June 2014
As at 30 June 2014 High Low Average
Share Price (pence) 1753.00 1777.00 1685.00 1744.43
Discount (debt at par) 4.6%
Discount (debt at fair 2.3%
value)
Source: Thomson Reuters Datastream
Assets and Gearing
30 June 2014
Total Gross Assets (£m) 280.4
of which cash and Certificates of Deposit (£m) 18.3
Borrowings (£m) 31.9
Cum Income Net Asset Value (pence) 1,837.9
Gross Gearing 12.8%
Net Gearing 5.5%
`Gross Gearing' reflects the amount of a company's gross borrowings and takes
no account of any cash balances. It is based on gross borrowings as a
percentage of shareholders' funds.
`Net Gearing' reflects the amount of net borrowings invested, i.e borrowings
less cash and bond holdings. It is based on net borrowings as a percentage of
shareholders' funds.
The Company's debt is provided by 250,000 5% cumulative preference shares of £1
each and the following debentures totalling approximately £32 million:
- £7,000,000 7.75% debenture stock 2020
- £24,968,300 debenture stock 2023
Industry Breakdown of Portfolio (excluding Cash and near cash)
30 June 2014
Financials 26.7%
Health Care 19.0%
Industrials 16.2%
Consumer Goods 15.8%
Consumer Services 8.1%
Telecommunications 6.6%
Utilities 5.1%
Oil & Gas 2.4%
Basic Materials 0.1%
100.0%
Top Ten Holdings
Investments % of Portfolio
British American Tobacco 4.9%
AstraZeneca 4.2%
Imperial Tobacco 4.2%
BT Group 4.0%
Reynolds American - US Common Stock 3.9%
Roche - Swiss Common Stock 3.6%
GlaxoSmithKline 3.4%
Reckitt Benckiser 2.8%
BAE Systems 2.8%
Novartis - Swiss Common Stock 2.6%
All ordinary shares unless otherwise stated
Changes to Share Capital
Ordinary Shares of 50p each
Issued
As at 31 Mar 2014 13,518,799
Shares bought back 0
Shares issued 0
As at 30 Jun 2014 13,518,799
The Company has authority to buy back shares for cancellation or to hold in
treasury and to issue new shares (disapplying pre-emption rights), in each case
within specified limits. The Company expects to renew these authorities each
year.
Price and Performance
The Company's Ordinary shares are listed on the London Stock Exchange and the
price is published in the Times and the Financial Times under `Investment
Companies' and in the Daily Telegraph under `Investment Trusts'.
The Company's net asset value is calculated on a daily basis and can be viewed
on the London Stock Exchange website at www.londonstockexchange.com
Further information can be obtained from Invesco Perpetual as follows:
Free Investor Helpline: 0800 085 8677
Internet address: www.invescoperpetual.co.uk/investmenttrusts
The information provided in this statement should not be considered as a
financial promotion.
For and on behalf of
Invesco Asset Management Limited
11 July 2014
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.